Startups
Edit
GBT (Global Blood Therapeutics, Inc.)
http://www.globalbloodtx.com/Last activity: 06.12.2021
Active
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Overview
Location
United States, California, South San Francisco
Employees
201-500
Total raised
$89.1M
Founded date
2011
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Perceptive Advisors | perceptivelife.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jan 6, 2015 | Series B round | $48M | |
| Jun 14, 2012 | Series A round | $40.7M |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 29, 2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| Jan 6, 2015 | Global Blood Therapeutics Closes $48M Series B Financing | Global Blood Therapeutics (GBT), a South San Francisco, CA-based biopharmaceutical company developing novel, small molecule therapeutics for the treatment of severe blood disorders, closed a $48m Series B financing. Backers included Welling... |
| Jan 6, 2015 | Global Blood Therapeutics Inks $48M Series B | SOUTH SAN FRANCISCO, CA, Biopharmaceutical company developing novel, small molecule therapeutics for the treatment of severe blood disorders, today announced the closing of a $48 million Series B financing. >> Click here for more f... |
| Jun 14, 2012 | Global Blood Therapeutics Raises $40.7M in Series A Financing | Global Blood Therapeutics, Inc., a San Francisco, CA-based newly formed product-focused company building a pipeline of oral for the treatment of chronic blood-based diseases and genetic disorders, has raised $40.7m in Series A financing fro... |
| Jun 14, 2012 | Global Blood Therapeutics Launches with $40.7M | SAN FRANCISCO, CA, Third Rock Ventures, LLC today announced the formation of Global Blood Therapeutics, Inc. and its $40.7 million Series A financing of the company. >> Click here for more funding data on Global Blood Therapeutics ... |
| Jun 14, 2012 | Venture firm launches rare blood disorder therapeutics developer with $41M | Among the company’s founders are three scientific researchers from University of California, San Francisco: Dr. Matthew Jacobson, Dr. Andrej Sali and Dr. Jack Taunton, and two Third Rock directors: Dr. Charles Homcy and Craig Muir. Dr. Mark... |
| Venture firm launches rare blood disorder therapeutics developer with $41M | Venture capital firm Third Rock Ventures has launched a drug development startup to treat genetic blood disorders, with sickle-cell anemia as its lead program target, providing $40.7 million in series A financing. Global Blood Therapeutics‘... |
Reviews 0
FAQ about GBT (Global Blood Therapeutics, Inc.)
When was GBT (Global Blood Therapeutics, Inc.) founded?
GBT (Global Blood Therapeutics, Inc.) was founded in 2011.
How much funding has GBT (Global Blood Therapeutics, Inc.) raised?
GBT (Global Blood Therapeutics, Inc.) has raised $89.1M in total across 3 funding rounds.
What funding rounds has GBT (Global Blood Therapeutics, Inc.) raised?
Parsers VC lists 3 funding rounds of GBT (Global Blood Therapeutics, Inc.), among them a Series B round of $48M on Jan 6, 2015 and a Series A round of $40.7M on Jun 14, 2012.
Who has invested in GBT (Global Blood Therapeutics, Inc.)?
Parsers VC lists 2 investors of GBT (Global Blood Therapeutics, Inc.), among them Perceptive Advisors.
What has the press written about GBT (Global Blood Therapeutics, Inc.)?
Parsers VC has collected 8 articles mentioning GBT (Global Blood Therapeutics, Inc.), among them “The biotech IPO feast flags as investors lose their appetite for R&D risk” (Jun 29, 2016) and “Global Blood Therapeutics Closes $48M Series B Financing” (Jan 6, 2015).
Is GBT (Global Blood Therapeutics, Inc.) still active?
Yes, GBT (Global Blood Therapeutics, Inc.) is active; its latest activity on Parsers VC dates from Dec 6, 2021.